Medical Condition

hematologic malignancies

Total Trials

7

Recruiting Now

7

Trial Phases

Phase 2, Phase 3, Phase 1

ClinicalMetric tracks all active clinical trials for hematologic malignancies sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematologic malignancies Clinical Trials

How many clinical trials are currently recruiting for hematologic malignancies?

ClinicalMetric currently tracks 7 actively recruiting clinical trials for hematologic malignancies, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for hematologic malignancies?

hematologic malignancies research spans Phase 1 (1 trial), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a hematologic malignancies clinical trial?

Eligibility criteria for hematologic malignancies trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Incyte Corporation 2 trials

National Heart, Lung, and Blood Institute (NHLBI) 1 trial

Milton S. Hershey Medical Center 1 trial

Asmaa Hassan mohamed Abdel Mawjoud 1 trial

University of California, Irvine 1 trial

Recruiting Clinical Trials

NCT05724121

Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

National Heart, Lung, and Bloo...

View Trial →

NCT06926595 Phase 2

Recruiting

Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Milton S. Hershey Medical Cent...

View Trial →

NCT04546945

Recruiting

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Asmaa Hassan mohamed Abdel Maw...

View Trial →

NCT06028828 Phase 2

Recruiting

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

University of California, Irvi...

View Trial →

NCT06465433 Phase 2

Recruiting

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Enrollment

25 pts

Location

Hungary, Italy, Sout...

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy

City of Hope Medical Center

View Trial →

NCT07195916 Phase 1

Recruiting

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Enrollment

280 pts

Location

United States, Austr...

Sponsor

Incyte Corporation

View Trial →

Related Conditions

allogeneic stem cell transplantation (2) chronic lymphocytic leukemia cll (1) waldenstr sqrroot delta m s macroglobulinemia (1) mantle cell lymphoma (1) sudden cardiac death (1) cardiac arrhythmias (1) graft versus host disease gvhd (1) allogeneic hematopoietic stem cell transplantation (1) solid tumors (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology